Author/Editor		Sinkovič, A
Title		Plasminogen activator inhibitor-1 in patients with atrial arrhythmias during acute myocardial infarction, treated with streptokinase
Type		članek
Source		Blood Coagul Fibrinolysis
Vol. and No.		Letnik 13, št. 8
Publication year		2002
Volume		str. 741-7
Language		eng
Abstract		Atrial arrhythmias (AA), especially atrial fibrillation (AF), during acute myocardial infarction (AMI) are often associated with increased mortality and heart failure. Impaired fibrinolysis with elevated plasminogen activator inhibitor-1 (PAI-1) activity is associated with resistance to fibrinolytic therapy in AMI patients, but it is also found in patients with AF. Our aim was a prospective study of the role of pre-treatment PAI-1 levels for the presence of in AMI patients and the influence of AA on in-hospital mortality. In 116 AMI patients, treated with streptokinase, pre-treatment PAI-1 levels were estimated by the chromogenic method (normal levels, 0.3-3.5 U/ml) and in-hospital AA were assessed as atrial fibrillation, flutter and/or tachycardias. Between patients with and without AA, a significant difference was observed in mean pre-treatment PAI-1 levels, in several in-hospital complications and mortality (24 versus 4.4%; P < 0.01; odds ratio, 6.45; 95% confidence interval, 1.66-25.0). The PAI-1 level > 7 U/ml was the most significant independent pre-treatment risk factor for AA (P < 0.05; odds ratio, 3.5; 95% confidence interval, 1.15-10.6). We conclude that AA were a significant risk for in-hospital mortality of AMI patients, treated with streptokinase. A pre-treatment PAI-1 level > 7 U/ml was the most significant pre-treatment risk for AA in these patients.
Descriptors		ARRHYTHMIA ATRIAL FIBRILLATION MYOCARDIAL INFARCTION PLASMINOGEN ACTIVATOR INHIBITOR 1 STREPTOKINASE MIDDLE AGE AGED SEX FACTORS PROSPECTIVE STUDIES PREDICTIVE VALUE OF TESTS HOSPITAL MORTALITY HEART ATRIUM ELECTROCARDIOGRAPHY DRUG THERAPY, COMBINATION